BANKA - Banka Bioloo

Banka BioLoo Limited has filed a mandatory annual declaration under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The promoters of the company have confirmed that they did not create any encumbrance or pledge on their shareholding during the financial year ended March 31, 2026. This routine filing is a standard transparency measure required by Indian market regulators. It confirms that the promoter's equity remains free from any debt-related liens or third-party obligations.

• Compliance with Regulation 31(4) of SEBI (SAST) Regulations, 2011 for the period ending March 31, 2026.
• Promoters confirmed zero encumbrances or pledges on their shares during the fiscal year.
• The declaration was officially submitted to the National Stock Exchange on April 3, 2026.
• Standard annual disclosure ensuring transparency in promoter shareholding patterns.

Banka BioLoo Limited has announced the resignation of Mrs. Nitika Lakhotia from the position of Company Secretary and Compliance Officer. The resignation was officially accepted on April 17, 2026, and her final day with the company will be April 30, 2026. The departure is attributed to her decision to pursue better career opportunities outside the organization. This is a standard administrative change and the company is expected to initiate the process of appointing a successor shortly.

• Mrs. Nitika Lakhotia resigned as Company Secretary and Compliance Officer effective April 30, 2026.
• The resignation was formally accepted by the company on April 17, 2026.
• The reason for cessation is cited as pursuing better career opportunities outside the company.
• The filing was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

Banka BioLoo Limited has responded to a clarification request from the National Stock Exchange regarding recent significant volatility in its share price. The company officially stated that it has made all necessary disclosures under Regulation 30 of SEBI (LODR) Regulations, 2015. Management confirmed there is no pending price-sensitive information or undisclosed announcements that could impact the stock's valuation. The company maintains that the recent price spurt is purely market-driven and not linked to any internal company developments.

• NSE issued clarification request Ref. No. NSE/CM/Surveillance/16696 on April 8, 2026.
• Company confirms compliance with all SEBI Listing Obligations and Disclosure Requirements.
• Management states no pending announcements exist that would impact the scrip price.
• Price movement attributed entirely to market conditions rather than company-specific news.
• Company denies sharing any price-sensitive information with market intermediaries.

Banka BioLoo Limited has approved the issuance of a corporate guarantee to secure credit facilities for its subsidiary, Megaliter Varunaa Private Limited. The guarantee covers an amount up to Rs 10 Crores in favor of Northern Arc Capital Limited. This commitment is unconditional and irrevocable, lasting until the subsidiary fully discharges its debt obligations. While it creates a contingent liability on a standalone basis, the company notes there is no impact on consolidated financials.

• Corporate guarantee issued for subsidiary Megaliter Varunaa Private Limited for up to Rs 10 Crores
• Credit facility to be provided by lender Northern Arc Capital Limited in one or more tranches
• Guarantee is unconditional and irrevocable, covering principal, interest, and other charges
• Transaction is at arm's length, though the parent company is a promoter of the borrower
• The guarantee will be recorded as a contingent liability on the standalone balance sheet

Banka BioLoo Limited has informed the exchange that its trading window will be closed starting April 1, 2026, for all designated persons and their relatives. This closure is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of financial results. The restriction pertains to the audited financial results for the quarter and financial year ending March 31, 2026. The window will reopen 48 hours after the results are officially declared to the exchange.

• Trading window closure begins on Wednesday, April 1, 2026
• Closure is related to the audited financial results for the quarter and year ending March 31, 2026
• Restriction applies to Directors, Designated Persons, and their immediate relatives
• Window will remain closed until 48 hours after the financial results are declared

Banka BioLoo Limited has approved the issuance of a corporate guarantee to support a credit facility for its subsidiary, Megaliter Varunaa Private Limited. The guarantee covers an amount up to ₹4.35 Crores in favor of Maanaveeya Development & Finance Private Limited. This is an unconditional and irrevocable guarantee that will remain in force until the credit facility is fully repaid. While it adds to the company's contingent liabilities on a standalone basis, it has no impact on the consolidated financial statements.

• Corporate guarantee issued for subsidiary Megaliter Varunaa Private Limited for up to ₹4.35 Crores.
• Guarantee provided to lender Maanaveeya Development & Finance Private Limited to secure credit facilities.
• The guarantee is unconditional and irrevocable until the full discharge of obligations.
• Transaction is confirmed to be at arm's length with no immediate impact on consolidated financials.
• The guarantee will be treated as a contingent liability on the company's standalone balance sheet.

Banka BioLoo Limited has received formal approval from the National Stock Exchange (NSE) for the listing and trading of 29,575 equity shares. These shares were issued following the exercise of options under the company's Employee Stock Option Plan (ESOP). The shares have a face value of Rs. 10 each and will be available for trading starting January 23, 2026. This is a routine administrative update following the allotment process.

• Listing and trading approval granted for 29,575 equity shares
• Shares issued under the Employee Stock Option Plan (ESOP)
• Effective date for dealings on the exchange is January 23, 2026
• Face value of the newly listed shares is Rs. 10 per share
• Distinctive numbers for the new shares are 10892858 to 10922432

Banka BioLoo Limited has approved the allotment of 29,575 equity shares following the exercise of options under its 2023 Employee Stock Option Plan. This allotment increases the company's total paid-up equity share capital from Rs. 10.89 crore to approximately Rs. 10.92 crore. The shares were issued at an exercise price of Rs. 10 per share, which is equal to the face value. The resulting equity dilution is marginal at approximately 0.27%, representing a standard administrative corporate action.

• Allotment of 29,575 equity shares of face value Rs. 10 each
• Total paid-up capital increased to Rs. 10,92,24,320 comprising 1,09,22,432 shares
• Exercise price for the options was set at Rs. 10 per share with zero premium
• The new shares rank pari-passu in all respects with existing equity shares

Banka BioLoo Limited has filed a compliance report for the quarter ended December 31, 2025, regarding SEBI (Depositories and Participants) Regulations, 2018. The company stated that Regulation 74(5), which concerns the processing of dematerialization requests, is not applicable to them for this period. This confirmation was backed by a letter from their Registrar and Share Transfer Agent, Bigshare Services Private Limited. This is a standard administrative filing with no impact on the company's financial health or operations.

• Compliance filing submitted for the quarter ended December 31, 2025
• Regulation 74(5) of SEBI (Depositories and Participants) Regulations declared not applicable
• Confirmation received from Registrar and Share Transfer Agent, Bigshare Services Private Limited
• Official notification dated January 5, 2026, sent to the National Stock Exchange

Banka BioLoo Limited has approved the grant of 21,000 stock options to eligible employees under its 2023 ESOP scheme. Each option is convertible into one equity share of face value Rs. 10, which also serves as the exercise price. The vesting is structured over a four-year period, with 25% of the options vesting annually starting from the first anniversary of the grant. This move is intended to incentivize and retain key personnel by aligning their interests with the company's performance.

• Grant of 21,000 options convertible into 21,000 equity shares of Rs. 10 each.
• Exercise price is set at the face value of Rs. 10 per share.
• Vesting schedule follows a 4-year timeline with 25% vesting each year.
• Exercise period is limited to 2 years from the date of each vesting tranche.
• The new shares issued will rank pari passu with existing equity shares.

Banka BioLoo Limited has announced the closure of its trading window effective from January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is a standard procedure ahead of the declaration of the company's unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all directors, designated persons, and their immediate relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be communicated at a later date.

• Trading window closure begins on January 1, 2026.
• Closure pertains to the unaudited financial results for the quarter and nine months ending December 31, 2025.
• Restriction applies to all Directors, Designated Persons, and their immediate relatives.
• Window will reopen 48 hours after the financial results are officially declared.
• Board meeting date for result approval to be announced in due course.